comparemela.com

Page 12 - Clinical Trials Arena News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Aslan s shot at approval jumps in gastric cancer after Phase II/III completes

Apart from gastric cancer, we also review Regenxbio in mucopolysaccharidosis type I and four Phase I trial updates.

Centric services forAslan pharmaceuticalsPipeline movesAslan pharmaceuticalOcular therapeutixPhase transition success rateSweden based anamarStemline therapeuticsClinical trials arenaUrte fultinaviciuteWhile loaCentric servicesAlternate site clinical trialsCost effective preclinical cancer model searches

Direct to patient: the rocky road to remote drug delivery in clinical trials

While an obvious solution to lockdown measures, direct-to-patient remote drug delivery is still an untapped opportunity in clinical trials.

Bhausaheb patilLeo pharmaDale hannaAndrea zobelKarla mackenzieAlexander pytlarzInfuserve americaMonitoring solutions for clinicalHealth insurance portabilityFlash groupTherapeutic goods administrationAdoption trackerTrials arenaClinical trials arenaAccountability actPrivacy rule

Oncorena begins Phase I/II trial of orellanine for advanced kidney cancer

Oncorena has started a Phase I/II trial of its drug candidate orellanine to treat individuals with advanced kidney cancer on dialysis.

Lars grundemarLaboratory equipmentSwedish medical products agencyDrug processing technologyClinical cancer studiesKarolinska university hospitalKarolinska hospitalClinical trials arenaProcessing technology

NorthSea begins intestinal failure associated liver disease therapy trial

NorthSea Therapeutics has commenced a Phase I trial of SEFA-6179 in adult subjects, to obtain a preliminary orphan indication to treat IFALD.

United kingdomTime data services for clinical researchNorthsea therapeuticsClinical trials arenaTime data servicesClinical researchKey challengesGlobal clinical trial

FDA grants clearance to begin Viridian s thyroid eye disease antibody trial

The US FDA cleared IND application of Viridian Therapeutics to commence Phase I trial of its antibody VRDN-002 to treat thyroid eye disease.

Laboratory equipmentDrug administrationDrug processing technologyViridian therapeuticsClinical trials arenaProcessing technologyKey challengesGlobal clinical trial

vimarsana © 2020. All Rights Reserved.